Revolution Medicines CEO Disposes Shares for Tax Obligations Under 10b5-1 Plan

Insider Transaction Overview

On September 18, 2026, Revolution Medicines, Inc. ($RVMD) filed a Form 4 on behalf of Mark A. Goldsmith, M.D., Ph.D., the company's President, Chief Executive Officer, and Director.

Key Details:

• Transaction Date: September 16, 2026
• Security: Common Stock
• Transaction Type: Open Market Sale (Code S)
• Shares Sold: 13,988 shares in total
  • 213 shares sold at a weighted average price of $195.0085 ($195.00 – $195.03)
  • 13,775 shares sold at a weighted average price of $199.3032
• Total Gross Value: ~$2,786,938.39
• Remaining Holdings:
  • Direct: 253,342 shares (includes 157,588 restricted stock units)
  • Indirect (Trusts): 716,908 shares held across multiple revocable trusts

Context and Significance:

• Significance Level: Low
• Purpose: According to the footnotes, these dispositions were made pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations triggered by the vesting of restricted stock units (RSUs).
• Because this was a non-discretionary "sell-to-cover" transaction under a long-standing 10b5-1 plan, it does not represent an opportunistic or sentiment-driven divestment by executive leadership.